Two Cases of Tumor-induced Osteomalacia Resulting in Surgical Resection During Burosumab Therapy

被引：0

作者：

Nagata, Dai ^{[1
]}

Takashi, Yuichi ^{[1
]}

Yamamoto, Mayuko ^{[1
]}

Toyokawa, Kyoko ^{[1
]}

Makihata, Kensuke ^{[1
]}

Koganemaru, Haruki ^{[1
]}

Hideshima, Saki ^{[1
]}

Muta, Yoshimi ^{[1
]}

Yokomizo, Hisashi ^{[1
]}

Fukumoto, Hironori ^{[2
]}

Nakayama, Shizuhide ^{[3
]}

Muta, Hiroko ^{[4
]}

Aoki, Mikiko ^{[4
]}

Abe, Hiroshi ^{[2
]}

Yamamoto, Takuaki ^{[3
]}

Hamasaki, Makoto ^{[4
]}

Kawanami, Daiji ^{[1
]}

机构：

[1] Fukuoka Univ, Sch Med, Dept Endocrinol & Diabet, Fukuoka, Japan

[2] Fukuoka Univ, Sch Med, Dept Neurosurg, Fukuoka, Japan

[3] Fukuoka Univ, Sch Med, Dept Orthoped Surg, Fukuoka, Japan

[4] Fukuoka Univ, Sch Med, Dept Pathol, Fukuoka, Japan

来源：

INTERNAL MEDICINE | 2025年

关键词：

tumor-induced osteomalacia; burosumab; fibroblast growth factor 23; postoperative monitoring; LOCALIZATION;

D O I：

10.2169/internalmedicine.4958-24

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Tumor-induced osteomalacia (TIO) is a rare paraneoplastic syndrome that results from tumors that secrete fibroblast growth factor 23 (FGF23). This leads to chronic hypophosphatemia. Burosumab, an anti-FGF23 antibody, is an effective treatment when surgery is not possible; however, it complicates FGF23 measurements and postoperative monitoring. We describe the first case report of TIO in which the responsible tumors were discovered during burosumab therapy and successfully resected. Despite tumor removal, the serum FGF 23 levels remained elevated. In the postoperative monitoring of patients treated with burosumab, physicians should focus on the serum and urine levels of phosphate rather than FGF23.

引用

页数：7

共 21 条

[1] Selective Venous Catheterization for the Localization of Phosphaturic Mesenchymal Tumors
Andreopoulou, Panagiota
Dumitrescu, Claudia E.
Kelly, Marilyn H.
Brillante, Beth A.
Peck, Carolee M. Cutler
Wodajo, Felasfa M.
Chang, Richard
Collins, Michael T.
[J]. JOURNAL OF BONE AND MINERAL RESEARCH, 2011, 26 (06) : 1295 - 1302
[2] The effect of burosumab on intact and C-terminal FGF23 measurements
Ashrafzadeh-Kian, Susan Louise
Ito, Nobuaki
Srivastava, Tarak
Garg, Uttam
Kato, Hajime
Algeciras-Schimnich, Alicia
Bornhorst, Joshua A.
[J]. CLINICAL ENDOCRINOLOGY, 2023, 99 (02) : 152 - 157
[3] Tumor localization and biochemical response to cure in tumor-induced osteomalacia
Chong, William H.
Andreopoulou, Panagiota
Chen, Clara C.
Reynolds, James
Guthrie, Lori
Kelly, Marilyn
Gafni, Rachel I.
Bhattacharyya, Nisan
Boyce, Alison M.
El-Maouche, Diala
Crespo, Diana Ovejero
Sherry, Richard
Chang, Richard
Wodajo, Felasfa M.
Kletter, Gad B.
Dwyer, Andrew
Collins, Michael T.
[J]. JOURNAL OF BONE AND MINERAL RESEARCH, 2013, 28 (06) : 1386 - 1398
[4] Tumor-Induced Osteomalacia
Florenzano, Pablo
Hartley, Iris R.
Jimenez, Macarena
Roszko, Kelly
Gafni, Rachel I.
Collins, Michael T.
[J]. CALCIFIED TISSUE INTERNATIONAL, 2021, 108 (01) : 128 - 142
[5] Florenzano Pablo, 2017, Bone Rep, V7, P90, DOI 10.1016/j.bonr.2017.09.002
[6] Most osteomalacia-associated mesenchymal tumors are a single histopathologic entity - An analysis of 32 cases and a comprehensive review of the literature
Folpe, AL
Fanburg-Smith, JC
Billings, SD
Bisceglia, M
Bertoni, F
Cho, JY
Econs, MJ
Inwards, CY
de Beur, SMJ
Mentzel, T
Montgomery, E
Michal, M
Miettinen, M
Mills, SE
Reith, JD
O'Connell, JX
Rosenberg, AE
Rubin, BP
Sweet, DE
Vinh, TN
Wold, LE
Wehrli, BM
White, FKE
Zaino, RJ
Weiss, SW
[J]. AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2004, 28 (01) : 1 - 30
[7] Phosphaturic mesenchymal tumor, mixed connective tissue type, non-phosphaturic variant: Report of a case and review of 32 cases from the Japanese published work
Honda, Rie
Kawabata, Yuka
Ito, Shusaku
Kikuchi, Fumihito
[J]. JOURNAL OF DERMATOLOGY, 2014, 41 (09) : 845 - 849
[8] Interim Analysis of a Phase 2 Open-Label Trial Assessing Burosumab Efficacy and Safety in Patients With Tumor-Induced Osteomalacia
Imanishi, Yasuo
Ito, Nobuaki
Rhee, Yumie
Takeuchi, Yasuhiro
Shin, Chan Soo
Takahashi, Yutaka
Onuma, Hiroki
Kojima, Masahiro
Kanematsu, Masanori
Kanda, Hironori
Seino, Yoshiki
Fukumoto, Seiji
[J]. JOURNAL OF BONE AND MINERAL RESEARCH, 2021, 36 (02) : 262 - 270
[9] Clinical utility of systemic venous sampling of FGF23 for identifying tumours responsible for tumour-induced osteomalacia
Ito, N.
Shimizu, Y.
Suzuki, H.
Saito, T.
Okamoto, T.
Hori, M.
Akahane, M.
Fukumoto, S.
Fujita, T.
[J]. JOURNAL OF INTERNAL MEDICINE, 2010, 268 (04) : 390 - 394
[10] Comparison of two assays for fibroblast growth factor (FGF)-23
Ito, N
Fukumoto, S
Takeuchi, Y
Yasuda, T
Hasegawa, Y
Takemoto, F
Tajima, T
Dobashi, K
Yamazaki, Y
Yamashita, T
Fujita, T
[J]. JOURNAL OF BONE AND MINERAL METABOLISM, 2005, 23 (06) : 435 - 440

← 1 2 3 →